Category - Developments

Developments

Vistagen posts positive Phase 3 results for nasal spray in social anxiety disorder

Vistagen (NASDAQ:VTGN) announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol nasal spray in adults diagnosed with social anxiety disorder...

August 7, 2023

Developments

LENZ partner cleared for Phase 3 presbyopia trial in China

LENZ Therapeutics’ China partner, Ji Xing Pharmaceuticals, was cleared by the Center for Drug Evaluation of the National Medical Products Administration of the PRC to conduct a Phase 3 clinical trial of LNZ100...

August 7, 2023

Developments

Mesoblast receives FDA complete response for BLA in GvHD

Mesoblast (NASDAQ:MESO, ASX:MSB) received a complete response letter to its biologics license application resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease...

August 4, 2023

Developments

Femasys begins pivotal trial of non-surgical permanent birth control candidate

Femasys (NASDAQ:FEMY) initiated enrollment in a prospective multi-center pivotal trial to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The trial is designed to...

August 3, 2023

Developments

Aravive flunks Phase 3 in platinum-resistant ovarian cancer

Aravive’s (NASDAQ:ARAV) Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre...

August 3, 2023

Developments

Oramed, Hefei Tianhui in JV to advance oral drug delivery technology

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) signed a non-binding term sheet with Hefei Tianhui Biotech to establish a joint venture based on Oramed’s oral drug delivery technology. The proposed JV would focus on...

August 2, 2023

Developments

NeuroBo in out-licensing with MThera Pharma

NeuroBo Pharmaceuticals (NASDAQ:NRBO) entered into a term sheet with MThera Pharma detailing terms that NeuroBo will out-license the worldwide rights, outside of Korea, for NB-01 for the treatment of painful diabetic...

August 2, 2023

Developments

Avenue Therapeutics achieves high potency and full efficacy in a model of generalized seizures

Avenue Therapeutics’ (NASDAQ:ATXI) BAER-101, its potentially best-in-class selective GABA-A alpha2,3 positive allosteric modulator significantly suppressed seizures in a translational animal model of absence epilepsy...

August 1, 2023

Developments

IntelGenx completes enrollment in Montelukast VersaFilm Phase 2a trial in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD). The company successfully...

August 1, 2023

Developments

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance broadening protection of Anixa Biosciences’ (NASDAQ:ANIX) novel ovarian cancer vaccine technology, which has been exclusively licensed from, and...

July 27, 2023

Category - Developments

Vistagen posts positive Phase 3 results for nasal spray in social anxiety disorder

LENZ partner cleared for Phase 3 presbyopia trial in China

Mesoblast receives FDA complete response for BLA in GvHD

Femasys begins pivotal trial of non-surgical permanent birth control candidate

Aravive flunks Phase 3 in platinum-resistant ovarian cancer

Oramed, Hefei Tianhui in JV to advance oral drug delivery technology

NeuroBo in out-licensing with MThera Pharma

Avenue Therapeutics achieves high potency and full efficacy in a model of generalized seizures

IntelGenx completes enrollment in Montelukast VersaFilm Phase 2a trial in AD

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

General

More